Comparison of vaginal micronized progesterone and combined intramuscular and vaginal progesterone for luteal phase support during in vitro fertilization - embryo transfer treatment in women &lt; 35 years

Abuzeid, O.; Hébert, J.; Abozaid, T.; Ashraf, M.; Abuzeid, Mostafa I.

doi:10.1016/j.fertnstert.2015.07.1075

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study results are similar to a retrospective cohort that compared both pregnancy rates and LBR after an IVF-ET in patients who used either vaginal micronized progesterone alone or those who used it along with Progesterone in the oil injection, and VP for luteal phase support (Abuzeid et al, 2015). It is also consistent with other studies that found no statistical clinical differences between VP and IMP in terms of patient preference, drug efficacy, safety IR, CPR, and LBR (Shapiro et al, 2014;Zaman et al, 2017;Tournaye et al, 2017).…”

Section: Discussionsupporting

confidence: 90%

Adding Weekly Intramuscular Progesterone to a Twice Daily Vaginal Progesterone Capsule for Luteal Phase Support in IVF/ICSI Cycles Results in Similar Live Birth Rates

Gari¹,

Al‐Jaroudi²

2022

JBRA Assisted Reproduction

View full text Add to dashboard Cite

Objective To compare pregnancy outcomes in patients undergoing artificial reproductive treatment (ART) and fresh embryo transfer (ET) who received twice-daily vaginal progesterone capsule (Cyclogest) alone verses twice daily vaginal progesterone capsule (Cyclogest) plus weekly intramuscular Hydroxyprogesterone Capronate (Proluton depot) for luteal phase support. Methods A retrospective cohort study that included 1162 patients who completed fresh ART/ET cycle from January 2015 to April 2018. Vaginal Cyclogest 400 mg twice daily was given to 985 patients following oocytes retrieval; whereas 177 patients received weekly intramuscular Proluton depot 250 mg in addition to twice-daily Cyclogest. The primary outcome was live birth rate. The secondary outcomes included biochemical pregnancy rate, clinical pregnancy, biochemical, and early and late pregnancy loss. Results There was no difference between the twice-daily vaginal progesterone and the addition of weekly intramuscular progesterone injections to the twice-daily vaginal progesterone regarding a positive pregnancy test (40.5% and 46.9%, respectively, p =0.112). There was no statistical difference in live birth rates between the groups (24% for group one, 26% for group two, p =0.582). Conclusions The administration of weekly intramuscular progesterone in addition to twice-daily vaginal progesterone capsule for luteal phase support post ART cycle does not result in higher live birth rate.

show abstract